The First Biological Choice in Patients with Rheumatoid Arthritis: Data from the Moroccan Register of Biotherapies

Overview

Journal Pan Afr Med J

Date 2021 May 17

PMID 33995789

Citations 2

Authors

Meryem Eddaoudi

Samira Rostom

Ihsane Hmamouchi

Imane El Binoune

Bouchra Amine

Redouane Abouqal

Lahsen Achemlal

Fadoua Allali

Imane El Bouchti

Abdellah El Maghraoui

Imad Ghozlani

Hasna Hassikou

Taoufik Harzy

Linda Ichchou

Ouafae Mkinsi

Redouane Niamane

Rachid Bahiri

Affiliations

Soon will be listed here.

Abstract

Introduction: the aim of our study is to determine, from data of the Moroccan register of biotherapies, the factors influencing the choice of the first prescribed biological treatment.

Methods: cross-sectional multicenter study including rheumatoid arthritis patients who were initiated the first biological treatment either: Rituximab, an anti-TNF, or Tocilizumab. The determinants related to the patient and disease have been gathered. A univariate and then multivariate analysis to determine the factors associated with the choice of the first bDMARDs was realized.

Results: a total of 225 rheumatoid arthritis patients were included in the Moroccan registry. The mean age was 52 ± 11 years, with female predominance 88% (n = 197). The first prescribed biological treatment was Rituximab 74% (n = 166), the second one was Tocilizumab, 13.6% (n = 31) then comes the anti-TNF in 3 position with 12.4% (n = 28). The factors associated with the choice of Rituximab as the first line bDMARDs prescribed in univariate analysis were: the insurance type, the positivity of the rheumatoid factor. In multivariate analysis, only the insurance type that remains associated with the choice of Rituximab as the first biological drugs. The Tocilizumab was associated with shorter disease duration and was more prescribed as mono-therapy compared to non Tocilizumab group. TNFi was associated with the insurance type.

Conclusion: our study suggests that Rituximab and TNFi are associated with the type of insurance and Tocilizumab is the most prescribed biologic mono-therapy in RA patients. Further studies are needed to confirm these results.

Citing Articles

Predictors of Drug Retention and Survival Rate of bDMARDs in Rheumatoid Arthritis: A Four-Year Real-Life Tunisian Experience.

Boussaid S, Tbini H, Rekik S, Khaled S, Rahmouni S, Zouaoui K Mediterr J Rheumatol. 2024; 35(3):448-458.

PMID: 39463880 PMC: 11500116. DOI: 10.31138/mjr.090723.pof.

Rheumatoid arthritis study of the Egyptian College of Rheumatology (ECR): nationwide presentation and worldwide stance.

Gheita T, Raafat H, El-Bakry S, Elsaman A, El-Saadany H, Hammam N Rheumatol Int. 2023; 43(4):667-676.

PMID: 36617362 PMC: 9995404. DOI: 10.1007/s00296-022-05258-2.

References

David J, Mattei R, Mauad J, de Almeida L, Nogueira M, Menolli P . Clinical and laboratory features of patients with rheumatoid arthritis diagnosed at rheumatology services in the Brazilian municipality of Cascavel, PR, Brazil. Rev Bras Reumatol. 2013; 53(1):57-65. DOI: 10.1016/s2255-5021(13)70006-3. View

McInnes I, Schett G . The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011; 365(23):2205-19. DOI: 10.1056/NEJMra1004965. View

Morsley K, Kilner T, Steuer A . Biologics Prescribing for Rheumatoid Arthritis in Older Patients: A Single-Center Retrospective Cross-Sectional Study. Rheumatol Ther. 2016; 2(2):165-172. PMC: 4883268. DOI: 10.1007/s40744-015-0021-z. View

Sugihara T, Harigai M . Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs. Drugs Aging. 2016; 33(2):97-107. PMC: 4756046. DOI: 10.1007/s40266-015-0341-2. View

Smolen J, Aletaha D, McInnes I . Rheumatoid arthritis. Lancet. 2016; 388(10055):2023-2038. DOI: 10.1016/S0140-6736(16)30173-8. View

Jones G, Sebba A, Gu J, Lowenstein M, Calvo A, Gomez-Reino J . Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2009; 69(1):88-96. PMC: 3747519. DOI: 10.1136/ard.2008.105197. View

Radovits B, Fransen J, Eijsbouts A, van Riel P, Laan R . Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology (Oxford). 2009; 48(8):906-10. DOI: 10.1093/rheumatology/kep129. View

Monti S, Klersy C, Gorla R, Sarzi-Puttini P, Atzeni F, Pellerito R . Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. Clin Rheumatol. 2017; 36(4):753-761. DOI: 10.1007/s10067-016-3528-y. View

Favalli E, Raimondo M, Becciolini A, Crotti C, Biggioggero M, Caporali R . The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. Autoimmun Rev. 2017; 16(12):1185-1195. DOI: 10.1016/j.autrev.2017.10.002. View

10.

Schiff M, Weinblatt M, Valente R, van der Heijde D, Citera G, Elegbe A . Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2013; 73(1):86-94. PMC: 3888617. DOI: 10.1136/annrheumdis-2013-203843. View

11.

Smolen J, Landewe R, Breedveld F, Buch M, Burmester G, Dougados M . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2013; 73(3):492-509. PMC: 3933074. DOI: 10.1136/annrheumdis-2013-204573. View

12.

Pattloch D, Richter A, Manger B, Dockhorn R, Meier L, Tony H . [The first biologic for rheumatoid arthritis: factors influencing the therapeutic decision]. Z Rheumatol. 2016; 76(3):210-218. DOI: 10.1007/s00393-016-0174-3. View

13.

Smolen J, Breedveld F, Burmester G, Bykerk V, Dougados M, Emery P . Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2015; 75(1):3-15. PMC: 4717393. DOI: 10.1136/annrheumdis-2015-207524. View

14.

Martin W, Shim M, Paulus H, Chaudhari S, Feng J, Elashoff D . Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry. J Clin Rheumatol. 2014; 20(6):301-5. PMC: 4560341. DOI: 10.1097/RHU.0000000000000152. View

15.

Jobanputra P, Maggs F, Deeming A, Carruthers D, Rankin E, Jordan A . A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years. BMJ Open. 2012; 2(6). PMC: 3532970. DOI: 10.1136/bmjopen-2012-001395. View

16.

Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K . Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013; 381(9877):1541-50. DOI: 10.1016/S0140-6736(13)60250-0. View

17.

Frisell T, Baecklund E, Bengtsson K, Di Giuseppe D, Forsblad-dElia H, Askling J . Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics. Ann Rheum Dis. 2017; 77(5):650-657. PMC: 5909744. DOI: 10.1136/annrheumdis-2017-212395. View

18.

Gabay C, Riek M, Hetland M, Hauge E, Pavelka K, Tomsic M . Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. Ann Rheum Dis. 2015; 75(7):1336-42. PMC: 4941183. DOI: 10.1136/annrheumdis-2015-207760. View

19.

Valim J, Chaer F, Guimaraes da Silveira F, da Silva E Lima V, de Souza B . Switching of biological therapies in Brazilian patients with rheumatoid arthritis. Future Sci OA. 2019; 5(1):FSO355. PMC: 6331703. DOI: 10.4155/fsoa-2018-0025. View

20.

Cantini F, Niccoli L, Nannini C, Cassara E, Kaloudi O, Favalli E . Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum. 2015; 45(5):519-32. DOI: 10.1016/j.semarthrit.2015.10.001. View